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ORIGINAL ARTICLE
Simultaneous alteration of de novo and salvage pathway to the
deoxynucleoside triphosphate pool by (E)-2?-Deoxy-
(fluoromethylene)cytidine (FMdC) and zidovudine (AZT) results
in increased radiosensitivity in vitro
PHILIPPE A. COUCKE1, ELIANE COTTIN2 & LAURENT A. DECOSTERD3
1Universite´ de Lie`ge, Centre Hospitalier Universitaire Vaudois, Department of Radiation Oncology, Domaine Universitaire du
Sart Tilman, Belgium, 2Laboratory of Radiation Biology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland,
and 3Laboratory of Clinical Pharmacology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Abstract
To test whether a thymidine analog zidovudine (/AZT), is able to modify the radiosensitizing effects of (E)-2?-Deoxy-
(fluoromethylene)cytidine (FMdC). A human colon cancer cell line Widr was exposed for 48 hours prior to irradiation to
FMdC. Zidovudine was added at various concentrations immediately before irradiation. We measured cell survival and the
effect of FMdC, AZT and FMdC/AZT on deoxynucleotide triphosphate pool. FMdC results in a significant increase of
radiosensitivity. The enhancement ratios (ER/surviving fraction irradiated cells/surviving fraction drug treated and
irradiated cells), obtained by FMdC or AZT alone are significantly increased by the combination of both compounds.
Adding FMdC to AZT yields enhancement ratios ranging from 1.25 to 2.26. FMdC reduces dATP significantly, with a
corresponding increase of TTP, dCTP and dGTP. This increase of TTP, dCTP and dGTP is abolished with the addition of
AZT. Adding AZT to FMdC results in a significant increase of the radiosensitizing effect of FMdC. This combination
appears to reduce the reactive enhancement of TTP, dCTP and dGTP induced by FMdC while it does not affect the
inhibitory effect on dATP.
Several chemotherapeutic compounds have been
tested to increase the response of tumor cells to
ionizing radiation. Some of these compounds inter-
act at the level of the nucleoside triphosphate
(dNTP) pool [14]. Perturbations of the dNTP-
pool have been shown to result in significant radia-
tion sensitization [1,58]. The cellular dNTP-pool
depends on de novo biosynthesis in which ribo-
nucleotide reductase (RR), dihydrofolate reduc-
tase (DHFR) and thymidylate synthetase (TS) are
key enzymes, and the salvage pathway in which
thymidine kinase (TK) plays a major role [912].
Hydroxyurea (HU), gemcitabine (dFdC) and
more recently (E)-2?-Deoxy-(fluoromethylene) cyti-
dine (FMdC) are known to act as inhibitors of
RR. All those compounds have been shown to be
able to sensitize tumor cells to ionizing radiation
both in vitro and in vivo [1,8,1122].
Inhibitors of RR are able to modify the pool of
dNTP. The change in the pool, especially the low-
ering of the dATP, will result in a modification of the
activity of the salvage pathway especially at the level
of TK. One might expect a reactive increase of
thymidine incorporation, resulting from an increased
activity of thymidine kinase (feedback loop on the
salvage pathway) [1,21,23,24]. Hence, we decided
to investigate whether, the radiosensitizing effect
observed after alteration of the de novo pathway by
FMdC, could be further modified through mani-
pulation of the salvage pathway, i.e. by presenting an
analog of thymidine to TK. The purpose of the
salvage pathway is to provide the cell with a low
supply of deoxynucleotides (e.g., for DNA repair)
during the time interval when the de novo synthesis is
not or less active. We used the thymidine analog
(TA) zidovudine (AZT) as this drug is known to
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interact at the level of TK and is widely used in
clinical practice as an inhibitor of reverse transcrip-
tase in the treatment of HIV infection.
The combination of FMdC with a TA, aimed at
modifying both the de novo pathway and the salvage
pathway, has been tested in vitro on a human colon
cancer cell line (WiDr). We selected a colorectal
cancer cell-line because there is usually a high
proliferative capacity and hence an increased TK
activity, which is known to be a marker of presence
of human neoplasia and/or disease progression in
many cancer [12,25]. We aimed at defining whether
the addition of AZT to FMdC yields increased
radiation induced cell death as compared to FMdC
alone and whether there is any more change in the
NTP and dNTP levels to eventually illustrate our
hypothesis.
Materials and methods
Chemicals and cell cultures
FMdC was kindly provided by Chiron Pharmaceu-
ticals, Inc. (San Francisco, California, USA). Zido-
vudine (AZT) was obtained from Wellcome
Research Laboratories (UK). Cell culture media
and supplements were from Gibco BRL (Basel,
Switzerland). Fetal calf serum (FCS) was purchased
from Fakola AG (Basel, Switzerland).
The cell line WiDr was purchased from American
Type Culture Collection (Rockville, Maryland,
USA). The cells were maintained in Minimum
Essential Medium with 0.85 g/l NaHCO3, supple-
mented with 10% FCS, 1% non-essential amino-
acids (NE-AA), 2 mM L-Glutamine, and 1%
penicillin-streptomycin solution. Cells were pas-
saged twice weekly. A test for mycoplasma was
routinely performed every 6 months, and found
negative for contamination.
Irradiation technique and clonogenic assay
Exponentially growing cells were trypsinized, and
seeded in 60/15 mm Falcon Primaria culture flasks
with 5 ml medium, allowed to attach and incubated
for 24 h before adding the inhibitor of RR. Medium
containing the chosen concentration of freshly pre-
pared FMdC was added thereafter and replaced at
24 h. After exposure to this drug, the cells were
trypsinized, and resuspended in fresh medium at low
density. Cells were plated into 100/20 mm Falcon
Primaria culture dishes containing 10 ml medium.
After a 3 h incubation in order to obtain cell
attachment, the cells were exposed to different
concentrations of AZT (25 mM, 50 mM and
100mM) added immediately prior to irradiation.
The cells were irradiated at room temperature
with an Oris IBL 137 Cesium source at a dose rate of
80.2 cGy/min. We used a range of single doses from
0 to 8 Gy, using a 2 Gy dose increment. For each
radiation dose (02468 Gy), four dishes were
utilized, both for control and drug-exposed cells.
The dishes were incubated at 37oC in air and 5%
CO2 for 2 weeks. The cells were fixed in ethanol,
stained with crystal violet, and the colonies were
manually counted. Colonies of more than 50 cells
were considered survivors. All experiments were
done in triplicate.
For all the data obtained by clonogenic assays, the
surviving fraction of drug treated cells was adjusted
for drug toxicity to yield corrected survivals of 100%
for unirradiated but drug treated cells. The effect
shown is therefore the sensitizing action, after the
substraction of the direct cytotoxic effect of each of
the drugs.
The impact of the different drugs (FMdC and
AZT) and the combination of each on the radiation
sensitivity of the WiDr cell line was calculated at
different survival levels (2, 20 and 50%).
Analysis of dNTP and NTP pools by gradient elution
ion-pair reversed phase high-performance liquid
chromatography (HPLC)
Simultaneous quantitation of dNTP and NTP in
WiDr cells was performed by gradient elution ion-
pair reversed phase HPLC with a modification of a
previously described method reported in detail else-
where [26]. Briefly, exponentially growing WiDr
cells were exposed to the drugs in the same experi-
mental conditions as for the clonogenic assays. The
cells were trypsinized, washed, centrifuged and
resuspended in ice cold ultrapure water (dilution
according to cells count) and deproteinized with the
same volume trichloroacetic acid (TCA) 6% (final
applied concentration/TCA 3%). Acid cell extracts
were centrifuged and the resulting supernatants
were stored at /808C prior to analysis. Before the
HPLC assay, samples were thawed and aliquots of
100 ml were neutralized with 4.3 ml saturated
Na2CO3 solution. In the present series of experi-
ments, aliquots of 25 ml were injected onto the
HPLC column with satisfactory sensitivity. All
experiments were done in triplicate, with the tripli-
cation process starting at the cell culture step, to
detect variability associated with the culture growth
conditions. Results were expressed as the concentra-
tion of the four dNTP (expressed in pMole/106 cells)
and as the absolute levels of the four NTP (as
measured by NTP peak areas). The optimization
and full validation of the analytical method is
described in detail elsewhere [26].
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Statistical analysis
Data are presented as the mean/the standard error
of three independent experiments. Surviving frac-
tions were compared using a two-sided paired t-test.
The difference was considered significant if a 0.05
p-value was reached. Dose response curves (from
0 to 8Gy), were fitted using a second degree
polynomial regression analysis, yielding a linear
quadratic equation. The curve fitting was obtained
using Statview 5.0 software on a MacIntosh G3
computer. From this linear quadratic equation we
calculated the ER values at 50%, 20% and 2%
survival levels.
Results
Effect of FMdC and AZT on clonogenicity
At a concentration of 30 nM there was no major
impact of FMdC on the plating efficiency (PE) of
WiDr cells as compared to untreated controls. The
data with AZT alone or combined to FMdC are
tabulated in Table I. At higher concentrations of
AZT (50 and 100 mM) there is a significant drop in
clonogenicity induced by the combination as com-
pared to each drug alone.
Effect on the radiation dose response curve
As illustrated in Figure 1, the use of FMdC alone
and AZT alone reduction of the shoulder of the dose
response indicating a radiation sensitizing effect.
The combination of AZT and FMdC, however,
yields a significant increase of the radiation sensitiv-
ity of the WiDr cell line as compared to each drug
alone combined to irradiation.
The calculated enhancement ratios (ER) at differ-
ent survival levels obtained from the linear quadratic
fitting of the curves are shown in Figure 2. At the low
concentration of FMdC (30 nM) the ER values for
survival levels ranging from 2 to 50% are ranging
from 1.18 to 1.28. AZT alone yields radiosensitiza-
tion especially at higher doses of AZT (50 and 100
mM). The largest effect, based on the ER value, is
obtained at clinical relevant radiation doses, i.e. in
the initial part of the radiation dose response curve
(see progression of the calculated ER values with
increasing survival level). When FMdC is combined
with AZT, the ER values are significantly increased
compared to each drug alone.
Effect of AZT and FMdC on dNTP pool measured by
HPLC
In order to obtain a clear cut and reproducible effect
of FMdC on the pools it was decided  based on
our previous published results  to use 50 nM and
100 nM instead of 30 nM which was the concentra-
tion used in the clonogenic assays.
All the data are grouped under Figure 3. The
HPLC analysis confirms our previous data: we
observe a highly significant reduction of the dATP
level with a corresponding increase of the dCTP and
TTP levels. As far as the NTP levels are concerned,
we reiterate the previous results i.e. a global increase
in the NTP levels which may in part be explained by
cell cycle redistribution [1].
Table I. Effect of FMdC (30 nM), AZT (range 25100 mM) and the combination on the plating efficiency of WiDr cells in vitro. Data are
given for as the mean value plus or minus standard error for 100 cells plated. All experiments have been done in triplicate.
FMdC AZT FMdC/AZT FMdC/AZT FMdC/AZT
Control 30 nM 25 mM 50 mM 100 mM 25 mM 50 mM 100 mM
1029/1.5 87.29/11.1 100.29/1.2 96.29/3.0 80.59/5.8 84.99/5.5 73.59/11.2 43.29/10.9
0.1
1
10
100
SF
%
0 2 4 6
Dose Gy
FMdC(30nM) + AZT(25/50/100microM)
FMdC+AZT(100)
FMdC+AZT(50)
FMdC+AZT(25)
AZT(100)
AZT(50)
AZT(25)
FMdC
Control
Figure 1. Dose reponse curve of WiDr cell line irradiated in vitro ;
upper curves illustrating the effect of AZT alone; lower curves
FMdC (30 nM/48 h) alone versus the combination with the
various concentrations of AZT. The data are plotted with
corresponding standard error (often contained within the size of
the symbols used).
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AZTat the lowest concentration (25 mM) does not
influence the dNTP levels compared to untreated
controls but at this low concentration, the combina-
tion with 50 nM FMdC yields a significant drop of
dCTP and TTP levels compared to FMdC treated
cells (data not shown). The combination of higher
doses of AZT with 50 nM FMdC results in a
significant decrease of dCTP and TTP as compared
to FMdC alone (Figure 3). In fact the reactive
increase of dCTP and TTP by FMdC is abbrogated
if FMdC is used in presence of AZT. The changes in
dGTP are less clear cut. On the other hand, AZT
does not seem to affect the clear decrease of dATP
induced by FMdC, but the levels of dATP are close
to the lowest detectable levels.
In summary, the combination of FMdC, known to
interact at the level of RR resulting in especially a
dATP drop and rise in TTP and dCTP, to AZT
results in a significant lowering of the levels of these
latter dNTP while for dGTP the effect is less
consistent.
Discussion
Radiation sensitivity of cell lines depends among
other factors on the pool of dNTP [1,68,27]. This
pool is regulated through two different pathways, the
de novo biosynthesis and the pyrimidine salvage
pathway. In the first pathway Ribonucleotide Re-
ductase (RR), Dihydrofolate Reductase (DHFR),
and Thymidylate Synthetase (TS) are key enzymes.
The enzyme RR is, however, the rate-limiting step in
the de novo pathway, whereas for the salvage pathway
thymidine kinase (TK) is the key enzyme [12].
Thymidine kinase is subject to feedback regulation
by dNTP, i.e. a reduction of dNTP results in an
increased activity of the salvage pathway (positive
feedback loop).
One of the first compounds active at the level
of RR to be used in a clinical setting has
been Hydroxyurea (HU). More recently, drugs
such as gemcitabine (2?,2?-difluoro-2?-deoxycyti-
dine/dFdC) and (E)-2?-Deoxy-(fluoromethylene)
cytidine (FMdC) have been developed as new
inhibitors of RR [28,29]. These compounds are
able to lower the dNTP-pool. Gemcitabine (dFdC)
is under active investigation as a radiosensitizer in
pancreatic cancer [7,8]. On the other hand, FMdC
has been shown to be on a variety of cell lines such as
colon (WiDr), cervix (C4-1, C-33-A, SiHa, Hela),
and breast (MCF-7) cancer cell lines [1,17,3033].
In some of those published data, radiosensitiza-
tion has been highlighted [1,5,1820]. The present
experiments aimed at demonstrating that radio-
sensitization observed at very low levels of FMdC
(30 nM) can substantially be modified by interacting
at the level of the salvage pathway.
There are at least three good rationales for
modulating TK in our experimental setting. First,
ionizing radiation is known to induce TK transcrip-
tion and enzymatic activity in human cells [34].
Second, it has been shown that cellular radioresis-
tance, at least in a rat glioma cell line, is related to
the expression of the thymidine kinase gene [35].
Third, in the case of inhibition of one of the key
enzymes in the de novo pathway, there will be an
increase of TK activity-as a result of the lowering of
one of the dNTP-and hence an increased capacity of
phosphorylation of thymidine analogs such as AZT,
resulting in incorporation and hence potentially
radiosensitization [14,36,37]. The utmost impor-
tance of TK in radiation response makes it an
attractive target to interact with either by reduction
of TK expression by targeted mutagenesis and
antisense strategies, or direct modulation of TK
itself. We decided to investigate this latter strategy.
We did already demonstrate the proof of principle in
an earlier paper using the combined effect of FMdC
and iodo-deoxy-uridine, but decided to use a com-
pound more readily available for clinical use [23].
From the research in AIDS, it is currently known
that the phosphorylation and hence anti-HIV activity
of AZT, can be substantially increased by modula-
tion of de novo pyrimidine biosynthetic pathway
by methotrexate and 5-fluoro-2?-deoxyuridine, espe-
cially at the level of DHFR and TS, respectively
[12,21,3638]. Based on this mechanism, some
investigators are combining AZT, 5-fluorouracil
and leucovorin in the treatment of metastatic colo-
rectal cancer [12,3941].
Kuo et al. highlighted the importance of simulta-
neous modulation of the de novo and salvage path-
0.5
1
1.5
2
2.5
ER
 -v
al
ue
s
0 10 20 30 40 50 60
Survival level in %
FM+AZT100
FM+AZT50
FM+AZT25
AZT100
AZT50
AZT25
FMdC
Figure 2. Effect of FMdC, AZT or the combination on the ER-
values, calculated from the linear quadratic equation, obtained at
survival levels of 2%, 20% and 50%.
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Figure 3 (Continued)
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Figure 3 (Continued)
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way. They demonstrated the effect of interaction of
hydroxyurea (HU) and iododeoxyuridine (IdUrd)
on the radiation sensitivity of the 647V cell line [42].
HU is an inhibitor of the M2 subunit of RR. This
drug lowers dATP, or at higher concentrations, acts
as a more general inhibitor of deoxynucleotide
biosynthesis. Inhibitors of RR are known to be able
to modify the radiation response both in vitro and in
vivo [1,5,8,13,1820,22,4345].The addition of
IdUrd to HU results in an increased radiosensitiza-
tion because the thymidine salvage pathway is
stimulated resulting in an increased incorporation
of IdUrd [42]. This thymidine analogue, incorpo-
rated in the dNTP pool after phosphorylation by
TK, has been shown to sensitize tumor cells to
ionizing radiation both in vitro and in vivo
[3,4,15,42,4649]. The radiosensitizing capacity
depends on the incorporation into DNA [7]; this
incorporation may be augmented by decreasing
competing TTP pools through feedback inhibition
of RR [6]. Therefore, exploiting the inhibition of RR
with a positive feedback regulation on TK through a
reduced dATP may result in a net increase of
incorporation of AZT, and hence an increased
susceptibility of DNA to single-strand breaks from
radiation-induced free radicals. The combination of
FMdC and AZT applied simultaneously yielded in
our hands a significant increase of the radiation
sensitivity of WiDr cells as compared to either
compound separately. We tentatively explain the
observation by speculating that incorporation of
phophorylated forms of AZT in DNA may result
in chain termination and DNA synthesis inhibition.
We have already published the potential of AZT
alone in specific experimental conditions to protect
cells against ionizing irradiation to a small degree
(ER about 1.1) [50]. However, as shown in the
present experiments, the combination of an inhibitor
of RR such as FMdC used at concentrations not
altering the PE, to a thymidine analogue such as
AZT, provide a powerful pharmacological tool to
obtain at least in vitro a significant increase of the
sensitivity of a WiDr cell line to ionizing radiation.
Moreover, these levels of ER’s are obtained at a
clinically relevant radiation dose level of 2 Gy, and at
concentrations of drugs which are clinically achiev-
able in humans.
In conclusion, these experiments provide supple-
mentary arguments in favor of the importance of
purine and pyrimidine de novo and salvage pathways
in the radiation response. As human tumor cells have
markedly elevated enzyme activity in these pathways,
there might be a differential effect with this biomo-
dulation between tumor and normal cells. The
colorectal model, as chosen in the present experi-
ments, is an ideal model because of the well known
difference in TK and RR activity as compared to
normal cells [11,12]. However, it remains to be
investigated whether this difference in enzymatic
activity between normal and tumor cells can serve
as a basis for a therapeutic differential effect ex-
ploitable in a clinical setting. Nevertheless, based on
the present in vitro data, the combination of FMdC
and AZT deserves in vivo experiments.
References
[1] Coucke PA, Decosterd LA, Li Y-X, et al. The ribonucleoside
diphosphate reductase inhibitor (E)-2?-deoxy-(fluoromethy-
lene)-cytidine as a cytotoxic radiosensitizer in vitro. Cancer
Research 1999;/59:/521926.
[2] Knol JA, Walker SC, Robertson JM, et al. Incorporation of
5-bromo-2?-deoxyuridine into colorectal liver metastases and
liver in patients receiving a 7 day hepatic arterial infusion.
Cancer Res 1995;/55:/368791.
[3] Miller EM, Fowler JF, Kinsella TJ. Linear-quadratic analysis
of radiosensitization by halogenated pyrimidines. I. Radio-
sensitization of human colon cancer cells by iododeoxyur-
idine. Radiat Res 1992;/131:/819.
[4] Miller EM, Fowler JF, Kinsella TJ. Linear-quadratic analysis
of radiosensitization by halogenated pyrimidines. II. Radio-
sensitization of human colon cancer cells by bromodeoxyur-
idine. Radiat Res 1992;/131:/907.
[5] Li Y-X, Coucke PA, Paschoud N, et al. Potentiation
of cytotoxicity and radiosensitization of (E)-2?-deoxy-2?-
(fluoromethylene)cytidine by pentoxifylline in vitro. Int J
Cancer 1999;/80:/15560.
[6] Shewach DS, Ellero J, Mancini WR. Decrease in TTP pools
mediated by 5-bromo-2?-deoxyuridine exposure in a human
glioblastoma cell line. Biochem Pharmacol 1992;/43:/1579
85.
[7] Shewach DS, Hahn TM, Chang E, et al. Metabolism
of 2?,2?-difluoro-2?-deoxycytidine and radiation sensitization
of human colon carcinoma cells. Cancer Res 1994;/54:/
321823.
[8] Shewach DS, Lawrence TL. Radiosensitization of human
tumor cells by gemcitabine in vitro. sem. Oncol 1995;/22:/
6871.
[9] Fox RM. Changes in deoxynucleoside triphosphate pools
induced by inhibitors and modulators of ribonucleotide
reductase. Pharmac Ther 1985;/30:/3142.
[10] Riddler SA, Andreson RE, Mellors JW. Antiretroviral activity
of stavudine (2?,3?-didehydro-3?-deoxythymidine, D4T).
Antiviral Res 1995;/27:/189203.
Figure 3. dNTP and NTP levels obtained from HPLC analysis of WiDr cells exposed to FMdC (50100 nM) and AZTat a concentration
of 25 (Figure 3A) and 50100 mM (Figure 3B). These concentrations were selected based on previous data aimed at optimizing the
interpretation of the HPLC technique [1,23,26]. FMdC induces an accumulation of ATP as a result of a cell cycle redistribution effect
[1,23]. AZTalone does not change the ATP pool. The major drop in dATP after addition of FMdC is not modified by the addition of AZT.
The increase in TTP induced by FMdC is significantly reduced by the addition of AZT. AZT alone has no effect as compared to controls.
The increase of dGTP pool and dCTP pool with FMdC is reduced by the addition of AZT. AZT alone has no effect.
618 P.A. Coucke et al.
D
o
w
n
lo
ad
ed
 B
y:
 [
Un
iv
er
si
ty
 o
f 
Li
eg
e]
 A
t:
 1
4:
18
 2
2 
Ja
nu
ar
y 
20
09
[11] Weber G. Biochemical strategy of cancer cells and the design
of chemotherapy. G. H. A. Clowes Memorial Lecture.
Cancer Res 1983;/43:/346692.
[12] Weber G, Ichikawa S, Nagai M, et al. Azidothymidine
inhibition of thymidine kinase and synergistic cytotoxicity
with methotrexate and 5-fluorouracil in rat hepatoma
and human colon cancer cells. Cancer Communic 1990;/2:/
12933.
[13] Davis MA, Tang H-Y, Maybaum J, et al. Dependence of
fluoro-deoxyuridine-mediated radiosensitization on S-phase
progression. Int J Radiat Biol 1995;/67:/50917.
[14] Lawrence TS, Davis MA, Maybaum J, et al. Modulation of
iododeoxyuridine-mediated radiosensitization by 5-fluorour-
acil in human colon cancer cells. Int J Radiat Oncol Biol
Phys 1992;/22:/499503.
[15] Lawrence TS, Chang EY, Hahn TM, et al. Radiosensitiza-
tion of pancreatic cancer cells by 2?,2?-difluoro-2?-deoxycy-
tidine. Int J Radiat Oncol Biol Phys 1996;/34:/86772.
[16] Levin VA, Prados MR, Wara WM, et al. Radiation therapy
and bromodeoxyuridine chemotherapy followed by procar-
bazine, lomustine and vincristine for the treatment of
anaplastic gliomas. Int J Radiat Oncol Biol Phys 1995;/32:/
7583.
[17] Matthews DP, Persichetti RA, Sabol JS, et al. Improved
synthesis of (E)-2?-deoxy-2?-(fluoromethylene)cytidine-a po-
tent inhibitor of ribonucleotide diphosphate reductase.
Nucleosides Nucleotides Nucleic Acids 1993;/12:/11523.
[18] Snyder RD. Effect of 2?-deoxy-2?-(fluoromethylene) cytidine
on the ultraviolet and x-ray sensitivity of HeLa cells. Oncol
Res 1994;/6:/17782.
[19] Sun L-Q, Li Y-X, Guillou L, et al. Antitumor and radio-
sensitizing effects of (E)-2?-Deoxy-(fluoromethylene)cyti-
dine, a novel inhibitor of ribonucleoside diphosphate
reductase, on human colon carcinoma xenografts in nude
mice. Cancer Res 1997;/57:/40238.
[20] Sun L-Q, Li Y-X, Guillou L, et al. (E)-2?-Deoxy-(fluoro-
methylene) cytidine potentiates radioresponse of two human
solid tumor xenografts. Cancer Res 1998;/58:/54117.
[21] Toffoli G, Errante D, Corona G, et al. Interactions of
antineoplastic chemotherapy with zidovudine pharmacoki-
netics in patients with HIV-related neoplasms. Cemother
1999;/45:/41828.
[22] Uhl V, Phillips TL, Ross GY, et al. Iododeoxyuridine
incorporation and radiosensitization in three human tumor
cell lines. Int J Radiat Oncol Biol Phys 1992;/22:/48994.
[23] Coucke PA, Cottin E, Azria D, et al. Positive interactive
radiosensitization observed in vitro with the combination of
two nucleoside analogs (E)-2’-deoxy-2’-(fluoromethylene)
cytidine (FMdC) and iododeoxyuridine (IdUrd). Eur J Can
2004;/40:/157280.
[24] Kanazawa J, Takahashi T, Akinaga S, et al. The relationship
between the antitumor activity and ribonucleotide reductase
inhibitory activity of (E)-2?-deoxy-2?-(fluoromethylene) cyti-
dine, MDL 101,731. Anti-Cancer Drugs 1998;/9:/6537.
[25] Hannigan BM, Xu Y-Z, Chubb S, et al. Thymidine kinases:
The enzymes and their clinical usefulness. Canc Biother
1993;/8:/18997.
[26] Decosterd LA, Cottin E, Chen X, et al. Simultaneous
determination of deoxyribonucleoside in the presence of
ribonucleoside triphosphates in human carcinoma cells by
high performance liquid chromotagraphy. Annal Biochem
1999;/270:/5968.
[27] Iliakis G, Kurtzmann S. Keynote address: Application of
non-hypoxic sensitizers in radiobiology and radiotherapy:
Rationale and future prospects. Int J Radiat Oncol Biol Phys
1989;/16:/123541.
[28] McCarthy JR, Matthews DP, Stemerick DM, et al. Stereo-
specific method to E and Z terminal fluoro olefins and its
application to the synthesis of 2?-deoxy-2?-fluoromethylene
nucleosides as potential inhibitors of ribonucleoside dipho-
sphate reductase. J Am Chem Soc 1991;/113:/743940.
[29] McGinn CJ, Shewach DS, Lawrence TS. Radiosensitizing
nucleosides. JNCI 1996;/88:/1193203.
[30] Bitonti AJ, Dumont JA, Bush TL, et al. Regression of human
breast tumor xenografts in response to (E)-2?-deoxy-2?-
(fluoromethylene)cytidine, an inhibitor of ribonucleoside
diphosphate reductase. Cancer Res 1994;/54:/148590.
[31] Bitonti AJ, Bush TL, Lewis MT, et al. Response of human
prostate tumor xenografts to (E)-2?-deoxy-2?-(fluoromethy-
lene)cytidine, an inhibitor of ribonucleotide reductase.
Anticancer Res 1995;/15:/117982.
[32] Piepmeier JM, Rabidou N, Schold SC, et al. In vitro and
in vivo inhibition of glioblastoma and neuroblastoma with
MDL101731, a novel ribonucleoside diphosphate reductase
inhibitor. Cancer Res 1996;/56:/35961.
[33] Wright PS, Cross-Doersen D, YH’NG JPH, et al. A
ribonucleotide reductase inhibitor MDL 101,731, induces
apoptosis and elevates TRPM-2 mRNA levels in hum-
an prostate tumor xenografts. Exper Cell Res 1996;/222:/
5460.
[34] Boothman DA, Davis TW, Sahijdak WM. Enhanced
expression of thymidine kinase in human cells following
ionizing radiation. Int J Radiat Oncol Biol Phys 1994;/30:/
3918.
[35] Al-Nabulsi I, Takamiya Y, Voloshin Y, et al. Expression of
thymidine kinase is essential to low dose radiation resistance
of rat glioma cells. Cancer Res 1994;/54:/56147.
[36] Ahluwalia GS, Gao W-Y, Mitsuya H, et al. 2?,3?-didehydro-
3?deoxythymidine: regulation of its metabolic activation by
modulators of thymidine-5’-triphosphate biosynthesis. Mol
Pharmacol 1996;/50:/1605.
[37] Pressaco J, Mitrovski B, Erlichman C, et al. Effects of
thymidylate synthase inhibition on thymidine kinase activity
and nucleoside transporter expression. Cancer Res 1995;/55:/
15058.
[38] Gong Y-F, Bechtold CM, Robinson BS, et al. Potentiation of
the stavudine anti-human immunodeficiency virus activity
by 5-fluorouracil. Antimicrob Agents Chemother 1996;/40:/
1329.
[39] Falcone A, Danesi R, Dargenio F, et al. Intravenous
azidothymidine with fluorouracil and leucovorin: A phase
I-II study in previously untreated metastatic colorectal
cancer patients. J Clin Oncol 1996;/14:/72936.
[40] Klein HO, Demir G. Multi-enzyme-targeted immunother-
apy. A salvage therapy protocol. Anticancer Res 1999;/19:/
34518.
[41] Posner MR, Darnowski JW, Weitberg AB, et al. High-dose
intravenous zidovudine with 5-fluorouracil and leucovorin.
A phase I trial. Cancer 1992;/15:/292934.
[42] Kuo M-L, Kunugi KA, Lindstrom M-J, et al. The interac-
tion of hydroxyurea and iododeoxyuridine on the radio-
sensitivity of human bladder cancer cells. Cancer Res 1995;/
55:/28005.
[43] Heinemann V, Xu Y-Z, Chubb S, et al. Inhibition of
ribonucleotide reduction in CCRF-CEM cells by 2?,2?-
difluorodeoxycytidine. Mol Pharmacol 1990;/38:/56772.
[44] Heinemann V, Schulz L, Issels RD, et al. Gemcitabine: A
modulator of intracellular nucleotide and deoxynucleotide
metabolism. Sem Oncol 1995;/22:/118.
[45] Vokes EE, Stupp R, Haraf D, et al. Hydroxyurea with
continuous infusion paclitaxel, 5-fluorouracil and concomit-
tant radiotherapy for poor prognosis head and neck cancer.
Semin Oncol 1995;/22:/4752.
Deoxynucleoside triphosphate pool and radiosensitivity 619
D
o
w
n
lo
ad
ed
 B
y:
 [
Un
iv
er
si
ty
 o
f 
Li
eg
e]
 A
t:
 1
4:
18
 2
2 
Ja
nu
ar
y 
20
09
[46] Deutsch M, Rewers AB, Redgate ES, et al. Intra-cerebral
ventricular infusion of 5-iodo-2-deoxyuridine (IUDR) as a
radiosensitizer in the treatment of rat glioma. Int J Radiat
Biol 1990;/19:/857.
[47] Erikson RL, Szybalski W. Molecular radiobiology of human
cell lines. III. radiation-sensitizing properties of 5-iodode-
oxyuridine. Cancer Res 1963;/23:/12230.
[48] Fornace AJ, Dobson PP, Kinsella TJ. Enhancement of
radiation damage in cellular DNA following unifilar sub-
stitution with iododeoxyuridine. Int J Radiat Oncol Biol Phys
1990;/18:/8738.
[49] Phillips TL, Bodell WJ, Uhl V, et al. Correlation of exposure
time, concentration and incorporation of IdUrd in V-79 cells
with radiation response. Int J Radiat Oncol Biol Phys 1989;/
16:/12515.
[50] Copaceanu M-L, Coucke PA, Cottin E, et al. Azidothymi-
dine (AZT) as a potential modifier of radiation response in
vitro. Acta Oncol 1995;/34:/2138.
620 P.A. Coucke et al.
D
o
w
n
lo
ad
ed
 B
y:
 [
Un
iv
er
si
ty
 o
f 
Li
eg
e]
 A
t:
 1
4:
18
 2
2 
Ja
nu
ar
y 
20
09
